AstraZeneca (LON:AZN) PT Set at GBX 5,000 by Goldman Sachs Group

Goldman Sachs Group set a GBX 5,000 ($65.33) price objective on AstraZeneca (LON:AZN) in a report published on Wednesday morning, Borsen Zeitung reports. The firm currently has a sell rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on AZN. Morgan Stanley upped their price target on SYSCO from $69.00 to $72.00 and gave the stock an equal weight rating in a report on Tuesday, May 7th. Liberum Capital restated a sell rating on shares of Pendragon in a report on Thursday, June 27th. UBS Group upgraded to a neutral rating and increased their target price for the company from GBX 945 ($12.35) to GBX 2,060 ($26.92) in a report on Thursday, June 20th. Bryan, Garnier & Co reiterated a neutral rating on shares of AstraZeneca in a report on Wednesday, July 3rd. Finally, Kepler Capital Markets set a €11.00 ($12.79) target price on E.On and gave the company a buy rating in a report on Monday, May 13th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of GBX 6,502.94 ($84.97).

AZN opened at GBX 6,324 ($82.63) on Wednesday. The firm has a market cap of $82.96 billion and a PE ratio of 33.28. The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66. The stock has a 50 day moving average price of GBX 6,247.96. AstraZeneca has a 1-year low of GBX 5,240 ($68.47) and a 1-year high of GBX 6,634 ($86.68).

In other AstraZeneca news, insider Philip A. J. Broadley acquired 520 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were acquired at an average price of GBX 5,738 ($74.98) per share, for a total transaction of £29,837.60 ($38,988.11). Also, insider Marc Dunoyer acquired 8,500 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were acquired at an average price of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Blue-Chip Stocks

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.